exRNAdisease

Entry Detail

---



General Information

Database ID: exR0084212 RNA Name: VAT1 RNA Type: mRNA Chromosome: chr17 Starnd: - Coordinate: Start Site(bp): 43014607 End Site(bp): 43025123 External Links: ENSG00000108828

Disease Information

Disease Name: Fragile X Syndrome Disease Category: Congenital, Hereditary, and Neonatal Diseases and Abnormalities MeSH ID: D005600 Type: Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities Alias: Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID: GSE83556 Description: Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions Experimental Design: Disease vs Control Case Disease Type: Fragile X Syndrome Case Disease SubType: NA Case Sample: Fragile X Syndrome Control Sample: Normal Number of Case: 22 Number of Control: 18 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABCC10 chr6 43427366 43450427 + ABHD17B chr9 71862452 71910931 - AC006486.1 chr19 42234583 42255132 - AC010422.3 chr19 12643831 12648397 - AC093525.2 chr16 2496032 2520218 + AC245033.1 chr15 82536788 82573194 - ACTB chr7 5527148 5563784 - ACTC1 chr15 34790230 34795549 - ACTG1 chr17 81509971 81523847 - ACTN1 chr14 68874143 68979440 - ACTN3 chr11 66546395 66563334 + ADAM15 chr1 155050566 155062775 + ADPGK chr15 72751369 72785846 - AIF1L chr9 131096476 131123152 + miRNA targets: miRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa-miR-23a-3p chr19 13836595 13836615 - hsa-miR-124-3p chr8 64379210 64379231 + hsa-miR-642a-5p chr19 45674943 45674964 + hsa-miR-769-5p chr19 46018961 46018982 + circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC008753.2 chr19 53788782 53789168 + AC020663.1 chr16 4730115 4752565 - AC026362.1 chr12 122975320 122982907 + AC245014.3 chr1 145281116 145281462 + AC245033.4 chr15 82533175 82540008 - Display:

Experiment Detail

GEO ID: GSE83556 Sample Source: Amniotic Fluid Source Fraction: Supernatant Platform: GPL570 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 17063 Sample treatment protocol: RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min). RNA Extract protocol: All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water. RNA library preparation protocol: RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference

PMID: NA Title: NA Author: NA Journal: NA Description: NA